Flamingo Therapeutics

Privately held: no public share price · Belgium

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
STAT3 antisense oligonucleotideRNA / oligonucleotide
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

August 2025Topline resultDanvatirsenDanvatirsen PEMDA-HN Phase 2 stopped: interim analysis negative
Flamingo Therapeutics · Source ↗

Financial reports

No financial reports recorded.